Role of the recently identified dysadherin in E-cadherin adhesion molecule downregulation in head and neck cancer

Medical Oncology

Volumn 29, Issue 3, 2012, Pages 1463-1467

  Georgolios, Alexandros ^a   Eleftheriadou, Anna ^b   Batistatou, Anna ^c   Charalabopoulos, Kostandinos ^d  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b General Hospital of Rethymnon   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

^d DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Adhesion molecules; Dysadherin; E cadherin; Head and neck cancer

Indexed keywords

CYCLIN D1; CYTOKERATIN; DYSADHERIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; SYNDECAN 1; UVOMORULIN;

CANCER CELL; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER SURVIVOR; COLORECTAL CANCER; CUTANEOUS MELANOMA; DOWN REGULATION; ENDOTHELIUM CELL; GLYCOSYLATION; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LIVER CELL CARCINOMA; LUNG CARCINOMA; LYMPHOCYTE; MALIGNANT TRANSFORMATION; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SURVIVAL RATE; THYROID PAPILLARY CARCINOMA; TONGUE CANCER; UNDIFFERENTIATED CARCINOMA;

CADHERINS; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84872811628     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0118-3     Document Type: Review

References (48)

1. Aoki S, Nakanishi Y, Akimoto S, et al. Prognostic significance of laminin-5 gamma2 chain expression in colorectal carcinoma: immunohistochemical analysis of 103 cases. Dis Colon Rectum. 2002;45(11):1520-7.
2. Batistatou A, Charalabopoulos K, Nakanishi Y, Vagianos C, Hirohashi S, Agnantis N, Scopa C. Differential expression of dysadherin in papillary thyroid carcinoma and microcarcinoma: correlation with E-cadherin. Endocr Pathol. 2008;19:197-202.
3. Batistatou A, Scopa C, Ravazoula P, et al. Involvement of dysadherin and E-cadherin in the development of testicular tumors. Br J Cancer. 2005;93(12):1382-7.
4. Batistatou A, Peschos D, Tsanou H. In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin. Br J Cancer. 2007;96(9):1404-8.
5. Batistatou A, Makrydimas G, Zagorianakou N, et al. Expression of dysadherin and E-cadherin in trophoblastic tissue in normal and abnormal pregnancies. Placenta. 2007;28(5-6):590-2.
6. Batistatou A, Charalabopoulos A, Scopa C, et al. Expression patterns of dysadherin and E-cadherin in lymph node metastases of colorectal carcinoma. Virchows Arch. 2006;448(6):763-7.
7. Bonitsis N, Batistatou A, Karantima S, et al. The role of E-cadherin/catenin complex in malignant melanoma. Exp Oncol. 2006;28(3):187-93.
8. Bosch FX, Andl C, Abel U, et al. E-cadherin is a selective and strongly dominant prognostic factor in squamous cell carcinoma: a comparison of E-cadherin with desmosomal components. Int J Cancer. 2005;114(5):779-90.
9. Charalabopoulos K, Binolis J, Karkabounas S. Adhesion molecules in carcinogenesis. Exp Oncol. 2002;24(4):249-57.
10. Charalabopoulos K, Mittari E, Karakosta A, et al. Integrins adhesion molecules and some of their ligands in laryngeal cancer. Exp Oncol. 2005;27(2):86-90.
11. Charalabopoulos K, Tsambalas S, Syrigos K, et al. Correlation of E-cadherin expression with clinicopathological data in patients suffering from transitional cell carcinoma of the bladder. Exp Oncol. 2003;25(3):180-5.
12. El-Hariry I, Pignatelli M. Adhesion molecules: opportunities for modulation and a paradigm for novel therapeutic approaches in cancer. Expert Opin Investig Drugs. 1997;6(10):1465-78.
13. Felding-Habermann B. Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis. 2003;20(3):203-13.
14. Georgolios A, Batistatou A, Manolopoulos L, et al. Role and expression patterns of E-cadherin in head and neck squamous cell carcinoma. J Exp Clin Cancer Res. 2006;25(1):5-14.
15. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993;53(15):3579-84.
16. Gupta A, Deshpande CG, Badve S. Role of E-cadherins in development of lymphatic tumor emboli. Cancer. 2003;97(9):2341-7.
17. Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol. 1998;153(2):333-9.
18. Ino Y, Gotoh M, Sakamoto M, et al. Dysadherin, a cancerassociated cell membrane glycoprotein, downregulates E-cadherin and promotes metastasis. Proc Natl Acad Sci USA. 2002;99(1):365-70.
19. Ioachim E, Peschos D, Goussia A, et al. Expression patterns of cyclins D1, E in laryngeal epithelial lesions correlation with other cell cycle regulators (p53, pRb, Ki-67, PCNA) and clinicopathological features. J Exp Clin Cancer Res. 2004;23(2):277-83.
20. Kawano T, Nakamura Y, Yanoma S, et al. Expression of E-cadherin, and CD44s and CD44v6 and its association with prognosis in head and neck cancer. Auris Nasus Larynx. 2004;31(1):35-41.
21. Kyzas PA, Stefanou D, Batistatou A, et al. Dysadherin expression in head and neck squamous cell carcinoma: association with lymphangiogenesis and prognostic significance. Am J Surg Pathol. 2006;30(2):185-93.
22. Lewis JE, Jensen PJ, Johnson KR, et al. E-cadherin mediates adherens junction organization through protein kinase C. J Cell Sci. 1994;107(Pt 12):3615-21.
23. Liang J, Zheng H, Xiao H, et al. Dysadherin expression in gastrointestinal stromal tumors. Pathol Res Prac. 2009;205:445-50.
24. Lubarski I, Pihakaski-Maunsbach K, Karlish SJ, et al. Interaction with the Na, K-ATPase and tissue distribution of FXYD5 (related to ion channel). J Biol Chem. 2005;280(45):37717-24.
25. Maehata Y, Hirahasi M, Aishima S, et al. Significance of dysadherin end E-cadherin expression in differentiated-type gastric carcinoma with submucosal invasion. Hum Pathol. 2011;42:558-67.
26. Maurizi M, Scambia G, Benedetti, Panici P, et al. EGF receptor expression in primary laryngeal cancer: correlation with clinicopathological features and prognostic significance. Int J Cancer. 1992;52(6):862-6.
27. Mitselou A, Ioachim E, Peschos D, et al. E-cadherin adhesion molecule and syndecan-1 expression in various thyroid pathologies. Exp Oncol. 2007;29(1):54-60.
28. Mitselou A, Batistatou A, Nakanishi Y, Hirohashi S, Vougiouklakis T, Charalabopoulos K. Comparison of the dysadherin and E-cadherin expression in primary lung cancer and metastatic sites. Hist Histopathol. 2010;25:1257-67.
29. Mittari E, Charalabopoulos A, Batistatou A, et al. The role E-cadherin/catenin complex in laryngeal cancer. Exp Oncol. 2005;27(4):257-61.
30. Moon C, Oh Y, Roth JA. Current status of gene therapy for lung cancer and head and neck cancer. Clin Cancer Res. 2003;9(14):5055-67.
31. Muramatsou H, Akimoto T, Maebayashi K, Kita D, Mitsuhashi N. Prognostic significance of dysadherin and E-cadherin expression in patients with head and neck cancer treated by radiation therapy. Anticancer Res. 2008;28:3859-64.
32. Nakamura E, Sugihara H, Bamba M, et al. Dynamic alteration of the E-cadherin/catenin complex during cell differentiation and invasion of undifferentiated-type gastric carcinomas. J Pathol. 2005;205(3):349-58.
33. Nakanishi Y, Akimoto S, Sato Y, et al. Prognostic significance of dysadherin expression in tongue cancer: immunohistochemical analysis of 91 cases. Appl Immunohistochem Mol Morphol. 2004;12(4):323-8.
34. Nam J, Hirohasi S, Wakefield L. Dysadherin: a new player in cancer progression. Cancer Lett. 2007;255:161-9.
35. Nishizawa A, Nakanishi Y, Yoshimura K, et al. Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients. Cancer. 2005;103(8):1693-700.
36. Ohene-Abuakwa Y, Pignatelli M. Adhesion molecules as diagnostic tools in tumor pathology. Int J Surg Pathol. 2000;8(3): 191-200.
37. Ohene-Abuakwa Y, Pignatelli M. Adhesion molecules in cancer biology. Adv Exp Med Biol. 2000;465:115-26.
38. Park J, Kim R, Lee Y, Kim S, et al. Dysadherin can enhance tumorigenesis by conferring properties of stem-like cells to hepatocellular carcinoma cells. J Hepatol. 2011;54:122-31.
39. Rhee D, Wenig BM, Smith RV. The significance of immunohistochemically demonstrated nodal micrometastases in patients with squamous cell carcinoma of the head and neck. Laryngoscope. 2002;112(11):1970-4.
40. Richards FM, McKee SA, Rajpar MH, et al. Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet. 1999;8(4):607-10.
41. Sanderson RJ, Montague ML. Surgical management of head and neck malignancy. Surgeon. 2004;2(1):7-14.
42. Sato H, Ino Y, Miura A, et al. Dysadherin: expression and clinical significance in thyroid carcinoma. J Clin Endocrinol Metab. 2003;88(9):4407-12.
43. Schuler Y, Lee-Thedieck C, Geiger K, et al. Osteoblast-secreted factors enhance the expression of dysadherin and CCL2-dependent migration of renal carcinoma cells. Int J Cancer. (2011). (Ep. in print).
44. Shimada Y, Hashimoto Y, Kan T, Kawamura, et al. Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma. Oncology. 2004;67:73-80.
45. Shimamura T, Sakamoto M, Ino Y, et al. Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: relationship to E-cadherin expression. J Clin Oncol. 2003;21(4):659-67.
46. Sturgis EM, Wei Q, Spitz MR. Descriptive epidemiology and risk factors for head and neck cancer. Semin Oncol. 2004;31(6): 726-33.
47. Tamura M, Ohta Y, Tsunezuka Y, et al. Significance of dysadherin expression in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2005;130(3):740-5.
48. Tsuiji H, Takasaki S, Sakamoto M, et al. Aberrant O-glycosylation inhibits stable expression of dysadherin, a carcinoma-associated antigen, and facilitates cell-cell adhesion. Glycobiology. 2003;13(7):521-7.